| All Releases |
|---|
 |
Progenics Board Approves $15 Million Share Repurchase Program
Apr 24, 2008
|
13.9 KB
|
| |
TARRYTOWN, N.Y., Apr 24, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its Board of Directors has approved a share repurchase program to acquire up to $15 million of its outstanding common shares.
Funding for the repurchase program will come from the $15 million milestone payment Progenics will rece...
|
|
|
Progenics and Wyeth Announce FDA Has Approved RELISTOR
Apr 24, 2008
|
19.1 KB
|
| |
TARRYTOWN, N.Y. & COLLEGEVILLE, Pa., Apr 24, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induc...
|
|
|
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Apr 24, 2008
|
14.8 KB
|
| |
COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received a positive opinion for RELISTOR™ (methylnaltrexone...
|
|
|
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Apr 1, 2008
|
18.2 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Apr 01, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that Wyeth has received marketing approval from Health Canada, the Canadian Regulatory Agency, for RELISTOR(TM) (methylnaltrexone bromide injection) for subc...
|
|
|
Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results
Mar 17, 2008
|
19.7 KB
|
| |
TARRYTOWN, N.Y., Mar 17, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2007.
Revenues for the fourth quarter ended December 31, 2007 totaled $15.5 million compared to $21.9 million for the same quarter in 2006. For the year ende...
|
|
|
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
Mar 12, 2008
|
17.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Mar 12, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced preliminary findings from the first of two phase 3 clinical trials of intravenous methylnaltrexone being evaluated for the management of postoperative ileus (...
|
|
|
Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
Jan 15, 2008
|
17.1 KB
|
| |
TARRYTOWN, N.Y., Jan 15, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of the phase 2 clinical program for PRO 140, an investigational drug for the treatment of human immunodeficiency virus (HIV) infection. Two, phase 2 clinical trials in HIV-infected individuals will investigate multiple dose...
|
|
|
Progenics and Wyeth Announce NDA Review Period for Subcutaneous Methylnaltrexone Extended by Three Months
Jan 10, 2008
|
17.2 KB
|
| |
TARRYTOWN, N.Y. & COLLEGEVILLE, Pa., Jan 10, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the action date for its review of the New Drug Application (NDA) for subcutaneou...
|
|
|
Progenics Pharmaceuticals CEO to Open NASDAQ Twice This Month
Nov 19, 2007
|
11.8 KB
|
| |
TARRYTOWN, N.Y., Nov 19, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chief Executive Officer and Chief Science Officer, will ring the NASDAQ stock market opening bell on Monday, November 19, 2007 to celebrate the company's ten year listing on NASDAQ.
...
|
|
|
Progenics Pharmaceuticals Inc. (PGNX) Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
Nov 16, 2007
|
13.1 KB
|
| |
ADVISORY, Nov 16, 2007 (PrimeNewswire via COMTEX News Network) --
What:
Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chief Executive
Officer and Chief Science Officer, will preside over the opening
bell. He will be joined by members of the Progenics management team.
Where:
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - ...
|
|
|
Progenics Pharmaceuticals Reports Third Quarter 2007 Results
Nov 8, 2007
|
19.8 KB
|
| |
TARRYTOWN, N.Y., Nov 08, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the third quarter and nine months ended September 30, 2007.
Revenues for the third quarter ended September 30, 2007 totaled $17.0 million compared to $17.8 million for the same quarter in 2006. For the fi...
|
|
|
Progenics Awarded $1.9 Million in NIH Grants for Novel Prostate Cancer Therapies
Nov 1, 2007
|
17.9 KB
|
| |
TARRYTOWN, N.Y., Nov 01, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the award of grants totaling $1.9 million by the National Institutes of Health (NIH). The proceeds, to be disbursed over two years, were awarded to support the development and initiation of clinical testing of a novel antibody-drug conjug...
|
|
|
Wyeth and Progenics to Initiate Phase 2 Trials of Oral Methylnaltrexone in Chronic-pain Setting
Oct 15, 2007
|
18.0 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Oct 15, 2007 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced plans to initiate two, four-week phase 2 clinical trials to evaluate daily dosing of oral methylnaltrexone in patients with chronic, non-malignant pain who are...
|
|
|
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Sep 20, 2007
|
13.5 KB
|
| |
TARRYTOWN, N.Y., Sep 20, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) announced today the pricing of an underwritten public offering of 2,600,000 shares of its common stock pursuant to an effective shelf registration statement. UBS Investment Bank, CIBC World Markets and Morgan Stanley acted as joint book-running managers ...
|
|
|
Wyeth and Progenics Initiate New Clinical Studies to Investigate Additional Patient Populations for Methylnaltrexone
Sep 11, 2007
|
19.5 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Sep 11, 2007 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced the initiation of three new clinical studies for their investigational drug, methylnaltrexone, a peripherally acting mu-opioid receptor antagonist.
Two of...
|
|
|
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Aug 29, 2007
|
17.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Aug 29, 2007 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that Wyeth has submitted a marketing application to the Therapeutic Goods Administration (TGA) division of the Australian Government. If approved, the compani...
|
|
|
Progenics Pharmaceuticals Reports Second Quarter 2007 Results
Aug 8, 2007
|
17.4 KB
|
| |
TARRYTOWN, N.Y., Aug 08, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the second quarter ended June 30, 2007 and the first half of 2007.
Revenues for the second quarter ended June 30, 2007 totaled $25.5 million compared to $19.1 million for the same quarter in 2006. For the...
|
|
|
Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting
Jul 25, 2007
|
24.1 KB
|
| |
SYDNEY, Australia, Jul 25, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented new findings from a phase 1b clinical trial of PRO 140 in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. At the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatme...
|
|
|
Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone
Jul 20, 2007
|
15.5 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Jul 20, 2007 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) and Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), today announced preliminary results from a phase 1 clinical trial of a new oral formulation of methylnaltrexone. Oral methylnaltrexone is an investigational drug being develope...
|
|
|
Progenics Selected to Present Clinical Results for Novel HIV Therapy PRO 140 at International Aids Conference
Jul 12, 2007
|
15.2 KB
|
| |
TARRYTOWN, N.Y., Jul 12, 2007 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that it has been selected to present results from a phase 1b clinical trial of PRO 140, an investigational drug for the treatment of HIV/AIDS, at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Preve...
|
|
|
